Share Name Share Symbol Market Type Share ISIN Share Description
Abingdon Health Plc LSE:ABDX London Ordinary Share GB00BLF79J41 ORD 0.025P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 4.50 4.00 5.00 4.50 4.50 4.50 151,277 00:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services - - - - 5

Abingdon Health PLC Settlement agreement signed with the DHSC

28/06/2022 10:38am

UK Regulatory (RNS & others)

Abingdon Health (LSE:ABDX)
Historical Stock Chart

From Jun 2022 to Dec 2022

Click Here for more Abingdon Health Charts.


RNS Number : 4557Q

Abingdon Health PLC

28 June 2022

Abingdon Health plc

("Abingdon" or "the Company")

Settlement agreement signed with the Department for Health and Social Care

York, U.K. 28 June 2022: Abingdon Health plc (AIM: ABDX), a leading international developer and manufacturer of high quality and effective rapid tests, notes recent bulletin board speculation and the rise in its share price.

The Company confirms that it has reached a settlement agreement with the Department for Health and Social Care ("DHSC") on the outstanding invoices payable by DHSC for lateral flow tests and component stock .

The Company notes that the settlement agreement only technically completes as and when the cash payment referred to below is received.

The settlement agreement is in full and final settlement of the outstanding debt of GBP8.9m (excluding interest) and comprises:

i) A contractually required cash payment of GBP6.3m from DHSC to Abingdon, which is required to be paid to the Company on or before 22 July 2022; GBP1.5m of this cash payment will be held under charge until the outcome of the judicial review is known; and

ii) transfer to the Company of ownership of the outstanding component stock that it had procured on behalf of DHSC in 2020/1; and

iii) joint-ownership, alongside DHSC, of the intellectual property of the AbC-19(TM) COVID-19 antibody test; and

iv) a lower royalty payable to DHSC on sales of the AbC-19(TM) COVID-19 antibody test, with this royalty time limited to one year from the date of the settlement agreement.

The monies received from DHSC, once received, will provide additional working capital and be deployed to help fund the Company's various growth initiatives underway.

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the Company's obligations under Article 17 of MAR.


 Abingdon Health plc                       
 Chris Yates, Chief Executive Officer                                 Via Walbrook PR 
 Melanie Ross , Chief Financial Officer 
 Dr Chris Hand, Non-Executive Chairman 
 Singer Capital Markets (Sole Broker and                     Tel: +44 (0)20 7496 3000 
  Nominated Adviser) 
 Peter Steel, Alex Bond (Corporate Finance) 
 Tom Salvesen (Corporate Broking) 
 Walbrook PR Limited              Tel: +44 (0)20 7933 8780 or 
 Paul McManus / Phillip                    Mob: +44 (0)7980 541 893 / +44 (0)7867 984 
  Marriage                                                                        082 
 Alice Woodings                                              Mob: +44 (0)7407 804 654 

About Abingdon Health plc

Abingdon Health is a world leading developer and manufacturer of high-quality rapid tests across all industry sectors, including healthcare and COVID-19. Abingdon is the partner of choice for a growing global customer base and takes projects from initial concept through to routine and large-scale manufacturing and has also developed and marketed its own labelled tests.

The Company offers product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health aims to support the increase in need for rapid results across many industries and locations and produces lateral flow tests in areas such as infectious disease, clinical testing including companion diagnostics, animal health and environmental testing. Faster access to results allows for rapid decision making, targeted intervention and can support better outcomes. This ability has a significant role to play in improving life across the world. To support this aim Abingdon Health has also developed AppDx(R) , a customisable image capturing technology that transforms a smartphone into a self-sufficient, standalone lateral-flow reader.

Founded in 2008, Abingdon Health is headquartered in York, England.

For more information visit:

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.



(END) Dow Jones Newswires

June 28, 2022 05:38 ET (09:38 GMT)

1 Year Abingdon Health Chart

1 Year Abingdon Health Chart

1 Month Abingdon Health Chart

1 Month Abingdon Health Chart
Your Recent History
Abingdon H..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20221209 22:03:46